شلل المعدة عندما لم يحقق العلاج المنشط للحركة من الخط الأول السيطرة على الأعراض

References

DOI: 10.1053/j.gastro.2025.08.004

• In individuals with gastroparesis, the AGA suggests against use of domperidone as a first-line treatment.
• In individuals with gastroparesis, the AGA suggests against the use of prucalopride as a first-line treatment.
• In individuals with gastroparesis, the AGA suggests against the use of aprepitant as a first-line treatment.
• In patients with gastroparesis, the AGA suggests against the use of nortriptyline as a first-line treatment.
• Clinical experience of the content experts on the panel suggests that tricyclic antidepressants should be started at low doses (10–25 mg), given at night to help avoid adverse effects, and increased slowly to maximize effect while minimizing risk of adverse effects.
• In patients with gastroparesis, the AGA suggests against the use of buspirone as a first-line treatment.
• In individuals with gastroparesis, the AGA suggests against the use of cannabidiol (CBD) except in the context of a clinical trial.
• The Guideline Panel Content Experts usually assess the efficacy of domperidone at 4–8 weeks to decide whether the treatment should be continued.